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The impact of myeloid malignancies on the nonhematopoietic components of the bone marrow remains
poorly understood. In this issue ofCell StemCell, Schepers et al. (2013) describe howmalignantmyeloid cells
alter the endosteal hematopoietic stem cell (HSC) niche, resulting in the expansion of osteoblastic lineage
cells that preferentially support malignant HSCs.Normal and leukemic stem cells receive a
complex array of cues from the bone
marrow niche that regulate their survival
and biological behavior. In this issue of
Cell Stem Cell, Schepers et al. (2013)
examine the reverse flow of information,
signals that emanate from neoplastic
hematopoietic cells that alter the biology
of the cells comprising the niche. These
pathologic interactions remodel multiple
cellular components of the bone marrow,
establishing a pathologic environment
that preferentially supports the neoplastic
cells, suppresses normal hematopoietic
stem cells (HSCs), and ultimately leads
to bone marrow fibrosis (Schepers et al.,
2013). A particularly compelling aspect
of this study is its use of a clinically rele-
vant in vivo murine model of myeloprolif-
erative neoplasms (MPNs) to determine
the changes that occur in the HSC niche
in the setting of malignancy and to
investigate how a corrupted, remodeled
endosteal niche contributes to disease
progression.
Many of the requisite cellular compo-
nents of the HSC bone marrow niche
have now been defined (reviewed in
Frenette et al., 2013). The endosteal
(also called ‘‘osteoblastic’’) niche is
defined anatomically by close proximity
to trabecular or cortical bone. Osteo-
blastic lineage cells (OBCs) are derived
from multipotent stromal cells (MSCs)
and play a key role in HSC maintenance
(Park et al., 2012). To examine the func-
tional impact of malignant myeloid cells
on the endosteal niche and the con-
sequent effects of the remodeled micro-
environment on normal and malignant
hematopoiesis, Scheppers et al. employ
an inducible BCR-ABL transgenic model
of chronic myelogenous leukemia (CML)(Koschmieder et al., 2005; Reynaud
et al., 2011), which is a subtype of MPN.
Examining bone marrow cell popula-
tions enriched for endosteal MSCs (Lin,
CD45, CD31, CD51+, Sca-1+) and their
OBC derivatives (Lin, CD45, CD31,
CD51+, Sca-1) (Winkler et al., 2010),
Schepers et al. make the striking ob-
servation that the number of OBCs is
increased in primary mice expressing
BCR-ABL. This expansion in OBCs is
associated with myelofibrotic changes
in the bone marrow, as indicated by
increased trichrome-positive staining
for collagen. OBC expansion is also
observed in wild-type recipient mice
transplanted with HSCs purified from
diseased mice expressing BCR-ABL.
Moreover, the authors demonstrate that
OBC expansion is reversible upon re-
exposure of diseased BCR-ABL mice to
doxycycline, thereby removing BCR-ABL
expression and eliminating the CML. In
aggregate, the results demonstrate that
MPN development is necessary and suffi-
cient for OBC expansion in the model.
Using an in vitro coculture assay,
Schepers et al. showed that OBC expan-
sion is driven by Mac-1+ myeloid MPN
cells acting on MSCs and that direct
cell-cell interaction or close-proximity
signaling is required to promote this
effect. They evaluated candidate cyto-
kines as soluble mediators of the
changes induced in endosteal BMstromal
cells in CML. The authors demonstrated
that both thrombopoietin (TPO) and
CCL3 (MIP1a) expand MSCs and that
this effect is potentiated in the presence
of wild-type bone marrow cells. They
then go on to characterize, using gene
expression profiling, the molecular
changes that occur in OBCs derivedCell Stem Cell 13, Sfrom diseased BCR-ABL-expressing
mice. OBCs from mice with CML had
elevated expression of genes involved in
extracellular matrix organization, regula-
tion of cell adhesion, and inflammatory
responses.
Finally, the authors demonstrated that
MPN-expanded OBCs are functionally
altered. MPN-expanded OBCs are
impaired in their ability to support normal
HSC activity but do not have diminished
capacity to supportBCR-ABL-expressing
neoplastic HSCs. On the basis of the
results of gene expression analyses, the
authors propose that the compromised
HSC-supportive activity of OBCs from
diseased CML mice relates to the
reduced expression of HSC retention
factors, such as Cxcl12, Scf, and Lepr,
and increased expression of molecules
such as Tgfb2, which promote myeloid
differentiation. Collectively, these results
indicate that the endosteal HSC niche is
remodeled in the presence of MPN, and
the resulting microenvironment preferen-
tially supports malignant stem cells.
While the alterations in the bone
marrow in response to a myeloid malig-
nancy are clearly complex, the authors
performed a meticulous and systematic
interrogation of the alterations in endos-
teal bone marrow stromal cells in MPN
and elucidated the functional conse-
quences of these changes on normal
and malignant HSCs (Figure 1). Their
detailed dissection of the pathological
interactions that occur between malig-
nant myeloid cells and the endosteal
HSC niche in CML advances the under-
standing of the pathogenesis of myelofi-
brosis and of the cell nonautonomous
mechanisms of clonal dominance in
MPN. Characterization of the earlyeptember 5, 2013 ª2013 Elsevier Inc. 257
Figure 1. Hematopoietic-Stromal Interactions in Chronic
Myelogenous Leukemia
Osteoblastic lineage cells (OBCs) obtained from mice expressing BCR-ABL in
the hematopoietic compartment are impaired in their ability to support normal
hematopoietic stem cells (HSCs) but are supportive of BCR-ABL-expressing
HSCs. Mac-1+ myeloproliferative neoplasm (MPN) cells are markedly
expanded and act on multipotent stromal cells (MSCs) to promote OBC
expansion. OBCs are increased in number, and this expansion is associated
with collagen deposition in the bone marrow. OBCs have an altered molecular
signature including reduced expression of HSC retention factors such as
Cxcl12, Scf, and Lepr. Aberrantly secreted cytokines contribute to paracrine
feedback loops. HSC, hematopoietic stem cell; MPN, myeloproliferative
neoplasm; MSC, multipotent stromal cell; OBC, osteoblastic lineage cell.
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Previewsmolecular changes that
occur in the endosteal niche
in myelofibrosis raises the
possibility that biomarkers
that predict the development
of myelofibrotic transforma-
tion in MPN could be identi-
fied. Interestingly, despite a
large body of evidence impli-
cating megakaryocytes in
the pathogenesis of myelofi-
brosis (Mullally et al., 2012),
Schepers et al. did not
observe any defects inmega-
karyopoiesis in mice ex-
pressing BCR-ABL, indi-
cating that other myeloid cell
populations are sufficient to
drive fibrotic transformation
in MPN. Future studies will
be needed to more fully char-
acterize the immunopheno-
type of Mac-1+ myeloid
MPNs that act on MSCs to
promote OBC expansion,particularly in view of the recently
described role of monocytes and macro-
phages as regulators of the HSC niche
(Winkler et al., 2010; Chow et al., 2011).
While myelofibrosis can occur in CML,
the major clinical challenge currently is
the treatment of primary myelofibrosis
or myelofibrosis that occurs as a sec-
ondary complication of polycythemia
vera (PV) or essential thrombocythemia
(ET). The majority of these BCR-ABL-
negative MPNs are driven by the
JAK2V617F oncogenic kinase. Although
JAK2 kinase inhibitors have been dis-
appointing in their ability to preferentially
target JAK2V617F mutant malignant258 Cell Stem Cell 13, September 5, 2013 ª2cells (Harrison et al., 2012), unlike the
efficacy of imatinib in CML, recent pre-
liminary reports suggest that JAK1/2
kinase inhibition over years may have
the potential to stabilize or improve
myelofibrosis (Kvasnicka et al., 2013,
J. Clin. Oncol., abstract). While these
results require validation, it is plausible
that suppressing the inflammatory cyto-
kine milieu through JAK1 and/or JAK2
kinase inhibition could contribute to
these effects. Ultimately, the findings
of Schepers et al. provide further
hope that therapeutic targeting of the
malignant hematopoietic clone could
reverse the pathologically remodeled013 Elsevier Inc.bone marrow, regenerating
a normal microenviron-
ment with resolved myelofi-
brosis that supports normal
hematopoiesis.
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